PWMG
XLO icon

Private Wealth Management Group’s Xilio Therapeutics XLO Stock Holding History

Private Wealth Management Group’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22
Closed -$199 – 1563
2025
Q4 		$199 Hold
22
– – ﹤0.01% 1433
2025
Q3 		$262 Hold
22
– – ﹤0.01% 1446
2025
Q2 		$211 Hold
22
– – ﹤0.01% 1453
2025
Q1 		$225 Hold
22
– – ﹤0.01% 1441
2024
Q4 		$297 Hold
22
– – ﹤0.01% 1475
2024
Q3 		$245 Buy
+22
New +$270 ﹤0.01% 1459

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Private Wealth Management Group's XLO Position: Q1 2026 in Review

Private Wealth Management Group sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 22 shares — an estimated $199 sold.

Private Wealth Management Group first reported a position in XLO in Q3 2024 and held it in 6 quarters. The position peaked at $297 in Q4 2024. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Private Wealth Management Group reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Private Wealth Management Group sold 22 Xilio Therapeutics shares in Q1 2026, an estimated $199.
  • Private Wealth Management Group first reported a position in Xilio Therapeutics in Q3 2024 and held it in 6 quarters.
  • Private Wealth Management Group's Xilio Therapeutics position peaked at $297 in Q4 2024.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Private Wealth Management Group's 13F filing for Q1 2026, filed 23 Apr 2026.